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A unique avian-origin A/H7N9 influenza virus has so far caused
134 cases with 44 deaths. Probing the host factors contributing
to disease severity, we found that lower levels of plasma inflam-
matory cytokines on hospital admission correlated with faster re-
covery in 18 patients with A/H7N9 influenza virus, whereas high
concentrations of (in particular) IL-6, IL-8, and macrophage inflam-
matory protein-1β were predictive of a less favorable or fatal out-
come. Analysis of bronchoalveolar lavage samples showed up to
1,000-fold greater cytokine/chemokine levels relative to plasma.
Furthermore, patients with the rs12252-C/C IFN-induced trans-
membrane protein-3 (IFITM3) genotype had more rapid disease
progression and were less likely to survive. Compared with
patients with the rs12252-T/T or rs12252-T/C genotype of IFITM3,
patients with the C/C genotype had a shorter time from disease
onset to the time point when they sought medical aid (hospital
admission or antiviral therapy) and a shorter interval to develop-
ment of the acute respiratory distress syndrome stage (reflected by
shorter intervals between clinical onset and methylprednisolone
treatments and higher rates of mechanical ventilator use), as well
as experiencing elevated/prolonged lung virus titers and cytokine
production and higher mortality. The present analysis provides
reported data on the H7N9 influenza-induced “cytokine storm” at
the site of infection in humans and identifies the rs12252-C geno-
type that compromises IFITM3 function as a primary genetic corre-
late of severe H7N9 pneumonia. Together with rs12252 sequencing,
early monitoring of plasma cytokines is thus of prognostic value for
the treatment and management of severe influenza pneumonia.
avian influenza | clinical outcome
In March 2013, an influenza outbreak caused by a unique avian-origin H7N9 influenza A virus emerged in the Yangtze River
Delta on China’s eastern seaboard (1–5). Along with other groups,
we characterized this human pathogen and established that the
2013-H7N9 HA is distinct from that of any previously identified
H7 influenza A virus (2). To date, the H7N9 virus has caused 134
confirmed cases in nine provinces. Most patients were hospitalized
with severe symptoms, particularly pneumonia (97.3%) and acute
respiratory distress syndrome (ARDS; 71.2%), leading to high rates
(75%) of intensive care unit admissions and mechanical ventilation
(66%), and >30% mortality (6, 7).
Our understanding of the relative contributions of viral and
host factors to severe influenza, including these H7N9 cases, is
far from complete. Multivariate analysis has shown that coex-
isting medical conditions are the only identified independent risk
factors to date for moderate to severe H7N9-associated ARDS
(6). It also seems that elevated concentrations of inflammatory
mediators in plasma (hypercytokinemia) are indicative of poor
disease outcomes in patients with H7N9 infections (5, 8). For
example, Chen et al. (5) observed substantially higher plasma
cytokine levels in a fatal case of H7N9 virus influenza compared
with those in a patient who survived. Zhou et al. (8) then found
that the circulating cytokines in H7N9-infected patients could
reach concentrations comparable to those characteristic of H5N1
pneumonia. Even so, although suggestive that hypercytokinemia
may predict, or reflect, severe disease following H7N9 infection,
such observations provide little insight into mechanisms. Further-
more, the question of whether plasma cytokine levels are a direct
reflection of what is happening in the infected lung has not been
explored previously for any human influenza pneumonia.
As with many influenza cases, it is far from clear why some (but
not all) H7N9-infected individuals develop very severe symptoms.
What is known is that the IFN-induced transmembrane protein-3
(IFITM3) can restrict influenza virus replication by preventing
endocytosed virus particles from entering the host cytoplasm
(9, 10). As a consequence, relative to the WT IFITM3+ /+
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controls, genetically disrupted IFITM3−/− mice are extremely
vulnerable to infection with even low pathogenic influenza viruses
(11). In humans, homozygosity for the SNP rs12252-C (C/C in
contrast to the WT T/T or F1 T/C) is associated with truncation of
the N-terminal 21 amino acids of the IFITM3 protein, which, in
turn, affects IFITM3 localization (12). This association of the C/C
phenotype with severe disease emerged from the analysis of hos-
pitalized patients in China (13) and Europe (11) during the 2009
H1N1 pandemic. However, because the pandemicH1N1 (pH1N1)
virus generally caused a mild infection, there was no a priori
reason to think that C/C individuals might be even more com-
promised by the highly pathogenic H7N9 strain.
What we show here is that the IFITM3 rs12252-C/C genotype
(vs. C/T or T/T) tends to be predictive of severe H7N9-induced
disease. In addition, early and persisting high cytokine/chemo-
kine levels in plasma [especially IL-6, IL-8, and macrophage
inflammatory protein (MIP)-1β] are associated with poor
clinical outcomes, although whether this is causative or simply
a consequence of greater and more prolonged virus replica-
tion is not altogether clear. Also apparent from the analysis of
bronchoalveolar lavage (BAL) samples is that at least some of
those high cytokine/chemokine concentrations in blood are
likely a “spillover” from local production in the infected lung. This
study thus suggests further approaches that might be used to probe
Table 1. Demographics, clinical information, and cytokine production of 18 H7N9 virus-infected patients
Group
Patient
no. Sex
Age,
y
Underlying
medical
disorders
Days from disease onset to
Initial
viral
load
1–2 d after
admission, pg/mL
CRP**,
mg/L
Clinical
outcome
(discharged
after days
of
onset or
death)
Cytokines/chemokines
Initiation
of
oseltamivir
First
methylprednisolone
treatment Admission
IL-
10*
IL-
6**
IL-
8**
MIP-
1β*
Group A
(recovery
outcome)
a73 M 53 None 5 5 6 2.82 2.4 9.4 7.6 4.4 24.4 14
a107 M 47 None 5 5 7 3.97 4.5 16.3 39.4 7.1 43.8 17
a49 M 68 Hypertension II 6 No 8 3.11 3.6 29 13.1 18.5 78.9 18
a10 M 65 Hypertension
arthritis
4 No 8 2.54 1.8 13.8 9.2 0 10.8 18
a134 F 74 Hypertension III,
coronary heart
disease (NYHA IV),
diabetes II,
cholecystitis
8 No 8 3.71 3.8 105.2 22.6 14.6 51.2 21
a78 M 74 None 8 12 10 <2 5.4 39.5 19 5.9 24.8 22
a20 F 81 Arrhythmia 5 6 6 3.49 15.7 134.6 47 26.6 131 23
a9 M 67 None 5 4 9 NA 7.6 76 20.3 25.4 45.1 23
a130 M 67 Diabetes II 11 9 9 NA 2.6 23.7 7.5 0 84 27
a79 M 78 Hypertension II 11 15 10 2.36 2.9 25.9 28.1 25.4 74.5 31
a11 F 75 Hypertension II,
coronary heart
disease (NYHA IV),
diabetes
8 9 9 3.05 12.8 17.4 18.6 0 106 33
a12 M 62 Hypertension 9 5 8 2.15 9.6 34.7 34.6 39 34.7 35
Average 67.7 7 7.7 8 3.02 6.1 43.8 22.3 13.9 59.1
Group B
(fatal
outcome)
a131 F 79 Arrhythmia,
coronary
heart disease
(NYHA IV),
chronic
bronchitis,
primary
biliary cirrhosis
6 6 8 4.75 16.9 88.6 110.7 84.6 82.5 Death
a22 M 58 Hypertension 9 8 12 <2 9.3 122 40.4 23 80.5
a33 M 56 None 3 7 8 26.2 146.9 42 31.7 115
a118 M 88 Hypertension III,
coronary heart
disease (NYHA IV),
diabetes II,
Chronic bronchitis
7 8 9 5.67 46.3 516.9 57.1 29.7 196
a150 M 80 None 7 7 15 <2 7.6 198 70.4 27.8 128
a90 M 74 Coronary heart
disease (NYHA III)
6 6 8 3.32 7.6 215.7 40 15.9 93.8
Average 68.5 6.3 7 10 4.58 19 214.7 60.1 35.5 120.1
All patients in group A recovered within 40 d after the onset of illness, and all patients in group B died. CRP, C-reactive protein; F, female; M, male; NA, not
available; NYHA, New York Heart Association.
*P < 0.05 between group A and group B; **P < 0.01 between group A and group B.
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mechanisms, while providing useful predictive measures of out-
come that should be of help in managing severe influenza.
Results
High Levels of Inflammatory Cytokines in Plasma Are Predictive of
Severe Clinical Outcomes. Following admission (ranging from day
6 to day 15 after onset of symptoms), we quantified inflammatory
cytokines in the plasma of confirmed H7N9 cases and correlated
the findings from these individual kinetic analyses with sub-
sequent clinical outcomes (Table 1). Most consistently elevated
were IL-6 and IL-8, whereas IL-10, MIP-1β, and IFN-γ were
increased at intermediate levels. Although IL-1β, TNF-α, and
MIP-1α were found in several patients, they were detected only
at minimal concentrations. Comparing cytokine production in
recovered patients discharged from our center by 35 d after onset
of illness (group A) with data from those who died (group B), we
found significantly higher levels (P < 0.01) of IL-6 and IL-8 in
the latter, more clinically compromised group (Fig. 1 A and B
and Table S1). All six patients in group B had plasma concen-
trations >80 pg/mL and ≥40 pg/mL for IL-6 and IL-8, respectively
(10-fold higher than normal), a profile found for only 1 (8.3%) of 12
patients in group A. It thus seems that very high blood levels of IL-6
and IL-8 are indicative of high risk of mortality from severe H7N9
influenza disease. Furthermore, IL-10 and MIP-1β were also ele-
vated in group B (Fig. 1 A and B and Table S1), although the dif-
ferences between groups A and B were less dramatic than for IL-6
and IL-8. Early and continued blood monitoring for these key in-
flammatory cytokines may thus be helpful for making appropriate
decisions regarding case management.
No bacterial infections during the early hypercytokinemia were
identified by clinical laboratory tests, possibly due to the fact that
the patients were receiving intensive antibiotic treatment before
their diagnosis with H7N9 virus. However, with the persistence of
inflammation, bacteria infection occurred in patients who showed
a huge blimp of inflammatory cytokines in their plasma (Fig. 1B).
Greatly Elevated Levels of Inflammatory Cytokines in the Pneumonic
Lung. As part of the clinical assessment, we collected BAL fluids
from three fatal cases. These were sampled at day 20 (a118), day
28 (a33), and day 33 (a22) after onset of illness. Plasma samples
were collected at the same time points. For these individuals,
levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, IFN-γ, MIP-1α, and
MIP-1β were substantially elevated for contemporary plasma and
BAL samples, with the BAL concentrations being 100-fold (MIP-1α
and MIP-1β) to 1,000-fold (IL-1β, IL-6, and IL-8) higher and
TNF-α being only detected in the BAL samples (Fig. 2A and Table
S2). Because we infused and collected ∼5 mL of BAL from the
right lower lobe, it is likely that cytokines were diluted during the
lung washing process. However, given that the plasma volume for
an adult human being is ∼2.7–3.0 L, it looks likely that those
mediators that are at very high relative levels in the BAL are pro-
duced locally in the infected lung and then spilled over into the
blood. This interpretation fits with the fact that in two of three
patients, the proportions (rather than absolute amounts) of the
different cytokines present in the BAL and plasma were very similar.
The huge differential in concentration between BAL and
plasma was not observed for IFN-γ and, to some extent, IL-10,
which could reflect dysfunctional antiviral immunity in patients
hospitalized with severe H7N9 infection. The fact that IFN-γ is
at equivalent concentrations in the BAL and plasma for two of
these three cases could also indicate that IFN-γ is either being
effectively consumed/used in the infected lung or that it is largely
produced in the lymphoid tissue. Overall, these findings suggest
that monitoring the plasma early for inflammatory cytokines/
chemokines is likely to be of prognostic value. Furthermore,
these data present the direct comparison of cytokine/chemokine
levels in BAL and plasma in severe human influenza pneumonia.
The severity of lung pathology was confirmed histologically for
two fatal cases. The profile of diffuse alveolar damage with ex-
tensive lymphocyte infiltration and hyaline membrane formation
observed for these patients is consistent with the idea that se-
creted inflammatory mediators are involved in lesion patho-
genesis (Fig. 2 C–F). Thickening of the alveolar interstitium,
together with extensive inflammatory cell infiltration partitioned
by small, flattened air spaces, was observed in one patient. Taken
together, all these data are supportive of the idea that greatly
elevated cytokine/chemokine levels are associated with the severe
lung damage and airway compromise that would be expected for
severe influenza pneumonia.
Association of the rs-12252-C Variant with Disease Severity. Given
that the SNP rs12252-C variant was associated with clinical
compromise and elevated plasma cytokine levels for the gener-
ally mild 2009 pH1N1 virus (11, 13), it seemed appropriate to
Fig. 1. Cytokines and chemokines associated with
severe H7N9 influenza infection in plasma and BAL
fluid. (A) Elevated levels of IL-10, IL-6, IL-8, and MIP-
1β in the patients’ plasma correlate with fatal clinical
outcomes, as specified in Table 1. Cytokine concen-
trations were assessed within 1–2 d after hospital
admission; patients who recovered and were dis-
charged within 35 d were assigned to group A (survival
group), and those died from the infection comprise
group B. (B) Kinetics of IL-6, IL-8, and MIP-1β levels in
plasma during the course of H7N9 infection, repre-
sented for (i) individual patients and (ii) group A vs.
group B, as outlined in Table S1. Cytokine and che-
mokines were measured with cytometric bead array
(CBA) kits.
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probe this correlation for our 16 hospitalized H7N9 patients.
Sequence analysis (Fig. 3A and Table S3) of peripheral blood
mononuclear cell DNA showed that 6 (37.5%) of 16 patients had
the C/C genotype, 7 (43.75%) of 16 patients had the T/C genotype,
and 3 (18.75%) of 16 patients had the T/T WT genotype. The
proportions of C/C and T/C individuals in our H7N9-hospitalized
patients were thus selectively increased relative to prevalence rates
of 26.5% (C/C), 36.5% (T/C), and 37% (T/T) in the normal (data
obtained from the 1,000 genome project) healthy Chinese pop-
ulation (Fig. 3A). Further examination of the clinical records
showed a trend in the time from disease onset to hospital admis-
sion within distinct IFITM3 groups, with the C/C cohort reporting
a mean of 6 d before seeking hospital admission, compared with
7.7 d for the T/C patients and 8.3 d for the T/T patients. Evidence
of more rapid disease progression (Fig. 3D and Table S3) was also
reflected in clinical decisions, leading to significantly reduced times
to first dosing with methylprednisolone (average of 5.5 d for C/C
patients and average of 12 d for T/T patients; P = 0.03), with one of
three T/T cases considered not to require this steroid treatment.
This pattern was also apparent for the first oseltamivir treatment,
with the intervals being 5.5 d for the C/C patients and significantly
increased to 9 d for the T/T patients (Fig. 3C; P = 0.02). A similar
trend was observed in mortality rates. Fatal outcomes were
recorded for 33.3% of the H7N9-infected C/C individuals, 28% of
the T/C group, and none of the WT T/T cases (Fig. 3F). Apart
from the increased trend in lethality, mechanical ventilation
[or extracorporeal membrane oxygenation respiratory assis-
tance (ECMO)] was required in four (66.7%) of six C/C ge-
notype patients, two (28%) of seven T/C genotype patients,
and one (33.3%) of three T/T genotype patients (Fig. 3E). In
view of the small number of patients with the WT T/T phe-
notype (n = 3), the reported trends also reflect a bias in
IFITM3 genotype distribution.
Reduced Capacity of rs-12252-C/C Genotype Patients to Control H7N9
Virus Replication. Our kinetic analysis indicated that the H7N9
influenza virus replicates actively between days 8 and 13 after
clinical onset. Analysis of peak virus titers (log10 copies per mil-
liliter, determined by real-time PCR for cDNA copies from throat
swabs in viral transport medium) showed that the C/C genotype
patients were less able to control H7N9 virus production, with four
of six showing titers >104, whereas that was true for only one of
five T/C genotype patients and none of the T/T genotype group
(Fig. 3B). Considering that the H7N9 influenza A virus is thought
to replicate 10- to 100-fold more in the human lung than in the
trachea (8), the difference between the mean value for C/C (103.9)
and T/T (103.0) genotypes in the trachea may be even more
striking for the deeper regions of the respiratory tract. All patients
were treated with oseltamivir, so it seems reasonable to assume
that this was not a confounding variable.
Increased Serum Levels of IL-6, IL-8, and MIP-1β in the C/C Genotype
Patients. Plasma levels of IL-6, IL-8, and MIP-1β were generally
higher in the C/C group vs. the T/C and T/T groups (Fig. 3G), as
suggested from the earlier pH1N1 study. Our data showed that
cytokine/chemokine levels were greatly elevated in the C/C
genotype patients compared with the T/C and T/T genotype
patients (Fig. 3G). Although all the T/T cohort had total cyto-
kine levels <150 pg/mL, four of six of the C/C cases had total
cytokine levels >150 pg/mL (Fig. 3G). Overall, our study pro-
vides an association of the IFITM3 C/C genotype with disease
severity and higher cytokine and chemokine levels in response to
H7N9 influenza virus infection.
Discussion
The newly identified H7N9 influenza A virus has caused a
number of fatalities (2–5, 7). Although infected children usually
suffer only a mild disease course (8), elderly subjects can be
much more severely affected (2–5), indicating that there is little
Fig. 2. Cytokine levels and lung histology in fatal
cases. (A) Massively increased levels of cytokines and
chemokines at the site of infection (BAL) compared
with plasma, measured for three individual patients
(a33, a22, and a118), as outlined in Table S2. (B)
Comparison of cytokine patterns between plasma
and BAL within individuals. (C–F) Diffused alveolar
damage with thickening of the alveolar interstitium
with extensive lymphocyte infiltration and hyaline
membrane formation was observed in the lung of
two H7N9-infected patients (a118 and a33). (C and
D) Arrows point to cellular infiltration into the
alveoli. (E and F) Normal lung samples from H7N9-
negative subjects are shown, with no inflammation
observed. Paraffin-embedded sections were stained
with H&E. (Magnification: C–F, 40×.)
772 | www.pnas.org/cgi/doi/10.1073/pnas.1321748111 Wang et al.
(if any) cross-protection from earlier influenza episodes and that
the decline in primary adaptive immunity with age is a determining
factor. Similar to what has been observed for the H5N1 pathogen
(14), our findings indicate that high levels of plasma inflammatory
cytokines/chemokines early in the course of the H7N9 infection
are correlated with severe clinical outcomes. As reported pre-
viously for H7N9 infection (5, 8), IL-6 and IL-8 are of particular
interest, with the concentrations being even higher than those
recorded earlier for H5N1-infected patients (8). In addition to
those earlier findings, the patient pool size and kinetic intensity
of the present sampling/analysis provide unique insights into the
correlation between hypercytokinemia and disease severity in
patients with H7N9 influenza virus infection.
Whether these greatly elevated cytokine/chemokine levels of-
fer an explanation for why the H7N9 virus causes such severe
disease, or are simply a correlate of inflammation and pathology,
cannot be determined from this type of analysis, but this kinetic
study does suggest an approach, based on early monitoring of
plasma cytokines, that could inform clinical decision making.
Why these particular cytokines are prominent, as distinct from
TNF-α, which shares a key signaling pathway with IL-6 and IL-8,
is not clear, although we have, of course, no information on rel-
ative rates of consumption, utilization, and/or degradation. The
analysis also suggests, but by no means proves, that much of the
plasma cytokine/chemokine pool is derived by diffusion from the
inflamed and infected respiratory tract. The concentrations of
inflammatory cytokines in the BAL were as much as 103-fold
higher than those found in plasma. It is likely of value to regard
the plasma as a “window” for IL-6 and IL-8 levels in the damaged
lung, an insight that has only been possible because we had the
opportunity to analyze several BAL samples from severely com-
promised individuals. Further studies are needed to compare viral
titers and cytokine levels in patients with milder influenza infec-
tions or severe seasonal influenza disease.
The respiratory tract represents an independent mucosal com-
partment, with innate and adaptive immune profiles that can
be distinct from those occurring at other organs or sites (15, 16).
Because most influenza A viruses multiply mainly in respiratory
epithelium, it is logical to think that the predominant innate and
adaptive immune responses reflect cellular recruitment to the
lung and, as part of the effort both to eliminate the pathogen and
to maintain the integrity of the organ, the local production of
a spectrum of cytokines and chemokines (17, 18). That in-
terpretation indeed fits with the unique, albeit limited, BAL
data. Of the prominent mediators found, IL-8 is known to pro-
mote the infiltration of neutrophils (19), whereas MIP-1α and
Fig. 3. Rs-12252-C association with disease severity
in patients hospitalized with a H7N9 influenza virus.
Due to the T→C nucleotide mutation at the
SNP12252 position, human IFITM3 can have three
homoforms (C/C with N-terminal 21 amino acids
truncated IFITM3, T/T with WT IFITM3, and F1 T/C).
(A) Comparison of allele frequencies in the normal
Chinese population (from the 1,000 genomes project)
and in patients with H7N9 virus from the SHAPHC.
Also shown are association of the rs-12252-C group
with higher influenza viral loads (quantified by real-
time RT-PCR on days 8–13 after disease onset) (B),
shorter time (days) from disease onset to oseltamivir
treatment (C), shorter time to first methylpredniso-
lone treatment (D), greater use of extracorporeal
membrane oxygenation or mechanical respiratory
ventilation (E), increased mortality rates (F), and ele-
vated cytokines/chemokines in plasma (G). In B,
dashed lines depict viral titres (log 10) of 2 and 4. In
G, dashed line refers to the highest cytokines/chemo-
kines level found for the T/T genotype.
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MIP-1β attract monocytes and macrophages (17, 18, 20). In
addition, little IL-10 was found in the BAL from three severe
cases, which may be reflective of unrestrained inflammation,
because the up-regulation of IL-10 is generally thought to
counterbalance, and prevent excessive immune activation. Fur-
thermore, the absence of IFN-γ from the BAL focuses attention
away from the roles that natural killer cells and T cells, which
tend to produce this cytokine in mice infected experimentally
with the H1N1 and H3N2 influenza A viruses, may play in this
infection. Whether IL-10 and IFN-γ could be of value for treat-
ment might be tested first in animal models.
The continued recruitment of immune cells into the lung
correlates with the progressive deterioration of oxygen exchange
and exacerbated hypoxia, leading finally to ARDS. Because
ARDS is the major cause for death in H5N1, severe acute re-
spiratory syndrome, and H7N9 infection, it is clearly a priority to
work out how we might attenuate such extreme functional com-
promise without delaying virus clearance. We need to know more,
and it is possible that expanding a spectrum of anti-inflammatory
treatment could be of benefit. Thus, the administration of immu-
nomodulators or giving IFN-α via aerosol or mechanical ventilation
might be considered. Because adaptive immunity develops mainly
in the secondary lymphoid tissues, any topical application of anti-
inflammatories via the respiratory tract may be less deleterious
than if larger amounts are given systemically.
The rs12252-C allele is found at an incidence of 25.8% in the
Beijing Chinese population, 27% in the southern Chinese pop-
ulation, and 38.2% in the Japanese population (data from the
1,000 genome project). Due to the high risk shown for pH1N1
(11, 13) and the prevalence of rs12252-C in these East Asian
cohorts, it was obviously important to study the role of this
specific SNP marker in H7N9 influenza infection. As reported
above, we found that compromised IFITM3 function is broadly
correlated with disease severity, indicating that early identifica-
tion of this defect may be beneficial for appropriate patient
management. What the correlation between high chemokine/
cytokine levels and the C/C phenotype further suggests is that we
need to develop a better benefit/risk understanding of the role of
these inflammatory mediators in respiratory disease. Further-
more, due to the association of rs12252-C with the severity of
both low pathogenic pH1N1 (13) and high pathogenic H7N9
(our study) infections, and because of the high frequency of the
C/C genotype in the Chinese population, it appears important
that the vaccination programs in East Asia recommend that
individuals with a C/C genotype be preferentially targeted for
routine influenza immunization. However, a thorough assess-
ment of the relative risk of vaccination, as well as its protective
efficacy in the C/C group, needs to be determined first.
In summary, our data demonstrate that inflammatory immune
responses linked to the C/C IFITM3 genotype during H7N9 in-
fection play an important role in the pathogenesis of the influenza
disease. Early screening for the IFITM3 genotype and monitoring
of inflammatory cytokines in plasma might help to evaluate
the severity of disease, and thereby to apply proper treatment
and management to prevent influenza-associated deaths.
Methods
Subjects and Samples.A total of 18 patients with H7H9 infection confirmed by
real-time PCR were admitted to the Shanghai Public Health Clinical Center
(SHAPHC). Plasma was collected every 2–3 d, and BAL samples were obtained
from three patients. The clinical information included patient demographics
plus daily monitoring of treatment, disease progression, and/or recovery.
Viral titers were determined by real-time PCR for cDNA copies from throat
swabs as log10 copies per milliliter of viral transport medium. Written in-
formed consent was obtained from all participants. The overall study was
reviewed and approved by the SHAPHC Ethics Committee.
Cytometric Bead Array Analyses of Cytokines and Chemokines. Cytokines and
chemokines in plasma and BAL fluid were quantified using a human in-
flammatory cytokine kit or a human soluble protein flex-set system (BD
Biosciences). Briefly, 30 μL of plasma or BAL was serially diluted and mixed
with various cytokine and chemokine capture beads, followed by PE de-
tection beads, and incubated in the dark at room temperature for 3 h.
Following acquisition on a BD FACSAria II (BD Biosciences), data were ana-
lyzed by CBA analysis software (BD Biosciences).
Sequencing and Genotyping of rs12252. Genomic DNA was extracted from
PMBCs using the QIAampDNA BloodMini Kit (Qiagen), and the exon 1 region
of IFITM3 containing rs12252 was amplified by PCR. The amplification was
performed using the following forward and reverse primers: 5′-GGAAA-
CTGTTGAGAAACCGAA-3′ and 5′-CATACGCACCTTCACGGAGT-3′ (Shanghai
Generay Biotech). The PCR products were purified and then sequenced on
an Applied Biosystems 3730xl DNA Analyzer (GATC Biotech). SNPs were
identified using Chromas (ABI).
Statistical Analyses. A parametric independent t test was used to calculate
P values for descriptive variables based on the assumptions of normal dis-
tribution and homogeneity of variance, and a nonparametric Mann–Whit-
ney test was used to calculate P values for variables not meeting the
assumptions of normal distribution and homogeneity. All statistical tests
were considered significant at P < 0.05, and data were analyzed using SPSS
software (IBM; version 17.0) and Prism 5 (GraphPad).
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Table S1. Kinetics of cytokine production of 18 H7N9 virus-infected patients
Group Patient no. Sex Age, y Days after onset of illness IL-6, pg/mL IL-8, pg/mL MIP-1β, pg/mL
A a73 M 53 6 9.4 7.6 4.4
9 38.5 0.0
13 0.0 0.0
a107 M 47 7 16.3 39.4 7.1
9 19.7 27.4 5.0
13 11.6 0.0
15 16.0 8.5
a49 M 68 9 29.0 13.1 18.5
10 21.0 6.3
14 16.2 0.0
18 0.0 0.0
a10 M 65 9 13.8 9.2 0.0
13 0.0 0.0
17 13.8 5.0
a134 F 74 8 105.2 22.6 14.6
11 19.7 67.3 45.0
17 21.0 16.0
a78 M 74 10 39.5 19.0 5.9
14 33.8 5.4
18 0.0 0.0
22 837.3 40.4
a20 F 81 6 134.6 47.0 26.6
10 110.5 170.9 50.0
14 37.0 110.6 18.5
20 60.0 7.0
a9 M 67 10 76.0 20.3 25.4
14 13.9 38.5 0.0
18 48.3 0.0
22 10.7 0.0
a130 M 67 10 23.7 7.5 0.0
11 0.0 0.0
13 14.8 0.0
17 0.0 0.0
a79 M 78 11 25.9 28.1 25.4
14 30.3 0.0
18 12.5 0.0
26 0.0 0.0
a11 F 75 10 17.4 18.6 0.0
13 11.6 42.1 8.5
17 11.8 53.3 0.0
27 25.2 0.0
a12 M 62 9 34.8 34.6 39.1
13 106.0 16.2
17 38.5 0.0
25 19.4 10.4
B a131 F 79 9 88.6 110.7 84.6
11 15.7 72.9 24.0
15 73.0 141.5 50.0
21 13.6 35.1 10.4
a22 M 58 24 122.0 40.4 23.0
28 45.5 44.3 10.4
32 23.2 48.3 76.3
40 34.2 53.0
a33 M 56 9 31.4 30.6 0.0
11 146.9 42.0 31.8
12 35.4 0.0
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Table S1. Cont.
Group Patient no. Sex Age, y Days after onset of illness IL-6, pg/mL IL-8, pg/mL MIP-1β, pg/mL
16 45.7 0.0
24 429.7 254.9 111.0
a118 M 88 10 516.9 57.1 29.7
12 52.5 211.1 34.0
16 25.4 82.5 14.0
20 1,394.0 1,935.0 69.0
a150 M 80 16 198.0 70.4 27.8
18 163.0 201.9
a90 M 74 9 215.7 39.9 15.9
11 9.4 30.7 0.0
MIP, macrophage inflammatory protein.
Table S2. Inflammatory cytokines in plasma and
bronchoalveolar lavage in H7N9 virus-infected patients
Inflammatory cytokines, pg/mL
Patient no.
a33 a22 a118
IL-10
Plasma 3.6 8.5 13.2
BAL* 59.4 9.9 42.8
IL-1β
Plasma 0 0 0
BAL 3,439 2,841.3 1,746.7
IL-6
Plasma 39.3 118.5 645.3
BAL 26,010 1,812.1 4,510.2
IL-8
Plasma 17.8 85.3 1,935
BAL 27,221 23,507 27,221
TNF-α
Plasma 0 0 0
BAL 654.5 24 28.6
MIP-1α
Plasma 0 15.6 0
BAL 1,630.2 625.6 349.6
MIP-1β
Plasma 11.3 246.2 138.5
BAL 6,277.6 1,191.7 603.8
IFN-γ
Plasma 2.6 2.6 8.3
BAL 11.9 1.8 4.6
*A 5-mL bronchoalveolar lavage (BAL) sample was collected from the right
lower lobe of each patient.
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Table S3. Association between rs12252 variants, time from disease onset to admission, virus titer, outcome of patients, and ventilation
intervention
Patient
no. rs12252
Days from disease onset to Virus titers at days after disease onset, log10
Outcome
Respiratory
assistanceOseltamivir
First
methylprednisolone
treatment Admission
Day
8
Day
9
Day
10
Day
11
Day
12
Day
13
Day
14
a9 C/C 5 4 9 <2 <2 ND ND ND ND ND Discharge
a33 C/C 3 7 2 ND 2.85 5.34 5.06 <2 <2 3.75 Death ECMO
a20 C/C 5 6 5 3.22 3.7 <2 3.04 <2 4.13 <2 Discharge Mechanical
a131 C/C 6 6 6 4.75 <2 ND <2 3 <2 <2 Death Mechanical
a12 C/C 9 5 8 ND 2.15 ND 5.76 <2 3.96 <2 Discharge Mechanical
a73 C/C 5 5 6 <2 <2 <2 <2 <2 <2 ND Discharge
a118 T/C 7 8 7 4.61 5.67 5.46 ND 3.55 5.35 5.03 Death ECMO
a49 T/C 6 No 7 3.11 3.35 <2 <2 <2 <2 <2 Discharge
a78 T/C 8 12 9 <2 <2 <2 <2 <2 <2 <2 Discharge
a107 T/C 5 5 5 <2 <2 <2 2.51 <2 <2 <2 Discharge
a10 T/C 4 No 5 ND <2 <2 ND <2 <2 2.21 Discharge
a22 T/C 9 8 12 <2 <2 <2 <2 ND ND <2 Death ECMO
a130 T/C 11 9 9 ND ND ND ND ND ND ND Discharge
a79 T/T 11 15 9 ND ND ND 2.36 <2 <2 <2 Discharge Mechanical
a134 T/T 8 No 7 3.71 <2 3.41 ND <2 <2 <2 Discharge
a11 T/T 8 9 9 ND 3.05 ND 2.44 <2 <2 <2 Discharge
Viral titers were determined by real-time PCR for cDNA copies from throat swabs in log10 copies per milliliter of viral transport medium. To confirm H7N9
infection, samples were collected from stools, urine, and plasma. H7N9 infection was diagnosed when one of those samples was tested positive by two
independent centers. ECMO, extracorporeal membrane oxygenation; ND, not determined.
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